A retrospective study conducted at the University Health Network found that, in liver transplant recipients with diabetes, combination therapy reduced HbA1c and alanine aminotransferase levels more effectively than DPP-4 inhibitors. Additionally, two clinical trials in patients with Type 2 diabetes demonstrated that combination therapy significantly lowered HbA1c by 1.34% and 1.21%, compared to a 0.54% reduction with placebo, starting from a baseline of 8.0%. These findings suggest that combination therapy may be especially beneficial in the liver transplant population, where patients often experience weight gain and develop metabolic co-morbidities
Does Wegovy, Mounjaro, or Ozempic cause hair loss
New oral options and changing manufacturer programs are shifting prices and access
A few small-scale studies have explored whether weight loss achieved through GLP-1 therapy might indirectly benefit patients with rheumatoid arthritis
The FDA has raised concerns about the increased risk of dosing errors, improper storage and fraudulently labeled GLP-1s from compounding pharmacies
yellowing of your skin or eyes
